Company: FENC
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001558370-25-005563
Chunk: 25

Company: FENNEC PHARMACEUTICALS INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 25
---
 |

| • | the advancement of our product candidates, both preclinical and clinical. |

Compensation Consultant In December 2024, the Compensation Committee retained Radford, an Aon company (“ Radford”), to provide assistance in reviewing the compensation for provide guidance on annual compensation for the Named Executive Officers and directors. The following table outlines fees paid to consultants in determining compensation paid to the Corporation’s directors and executive officers:

| ​                                   
 ​                                   
 ​                                   | ​ | ​ 
 ​ 
 ​ |           ​ 
 Fiscal Year 
        2024 | ​ | ​ 
 ​ 
 ​ |           ​ 
 Fiscal Year 
        2023 |
|:------------------------------------|:--|:--|------------:|:--|:--|------------:|
| Executive Compensation-Related Fees |   | $ |      59,000 |   | $ |       4,213 |
| All Other Fees                      |   | ​ |           — |   | ​ |           — |
| Total                               | ​ | $ |      59,000 | ​ | $ |       4,213 |

Benchmarking Radford’s engagement included conducting a review of Fennec’s peer group of companies to ensure the ongoing suitability and applicability of such group, as certain of Fennec’s compensation matters are compared against the peer group. Based on the review by Radford and in consultation with the Compensation Committee and the Board, a peer group consisting of the following 20 companies was chosen on the basis of the following characteristics in relation to Fennec: (i) operating in the biotechnology and pharmaceutical industries; and (ii) market capitalization, employee size and stage of development:

Page16

Aadi Bioscience, Aldeyra Therapeutics, Anavex Life Sciences, BioXcel Therapeutics, Checkpoint Therapeutics, Chimerix, Clearside Biomedical, Delcath Systems, Eton Pharmaceuticals, Heron Therapeutics, Invivyd, Journey Medical, Outlook Therapeutics, scPharmaceuticals, SCYNEXIS, SIGA Technologies, X4 Pharmaceuticals and Y-mAbs Therapeutics. This peer group was used to help evaluate compensation design precedents and trends, and for guiding the calibration of competitive pay levels. Compensation Risk The Board considers and assesses, as necessary, the implications of risks associated with Fennec’s compensation policies and practices and devotes such time and resources as it believes are appropriate given Fennec’s size and stage of development. The Corporation